Potential implications of lactoferrin as a therapeutic agent

American Journal of Veterinary Research

Volumn 66, Issue 4, 2005, Pages 739-742

  Larkins, Nicholas ^a  

^a Nutritional Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; APOLACTOFERRIN; COUMARIC ACID; FERULIC ACID; INTERLEUKIN 1; IRON BINDING PROTEIN; LACTOFERRICIN; LACTOFERRICIN B; LACTOFERRIN; MESSENGER RNA; PHENOL DERIVATIVE; PREBIOTIC AGENT; TRANSFERRIN; TYROSOL; UNCLASSIFIED DRUG;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIFIDOBACTERIUM; CANDIDA ALBICANS; CLOSTRIDIUM; DRUG BINDING; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ESCHERICHIA COLI; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOREGULATION; LACTATION; LARGE INTESTINE CANCER; MILK; NONHUMAN; PORPHYROMONAS GINGIVALIS; PREVOTELLA INTERMEDIA; PREVOTELLA NIGRESCENS; PROTEIN SYNTHESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; ROTAVIRUS; STREPTOCOCCUS; VIRUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ANTIVIRAL AGENTS; CATTLE; CATTLE DISEASES; LACTOFERRIN;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; CANDIDA ALBICANS; CLOSTRIDIUM; ESCHERICHIA COLI; HEPATITIS C VIRUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; PORPHYROMONAS GINGIVALIS; PREVOTELLA INTERMEDIA; PREVOTELLA NIGRESCENS; RESPIRATORY SYNCYTIAL VIRUS; ROTAVIRUS; STREPTOCOCCUS;

EID: 17544365665     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.739     Document Type: Review

References (69)

1. Inoue M, Yamada J, Kitamura N, et al. Immunohistochemical localization of lactoferrin in bovine exocrine glands. Tissue Cell 1993;25:791-797.
2. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995;80:252-267.
3. Lönnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995;15:93-110.
4. Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv Exp Med Biol 1994;357:133-141.
5. Borregaard N, Lollike K, Kjeldsen L, et al. Human neutrophil granules and secretory vesicles. Eur J Haematol 1993;51:187-198.
6. Masson PL, Heremans JF. Studies on lactoferrin, the iron-binding protein of secretions. Protides Biol Fluids 1966;14:115-124.
7. Spik G, Coddeville B, Mazurier J, et al. Primary and three-dimensional structure of lactotransferrin (lactoferrin) glycans. Adv Exp Med Biol 1994;357:21-32.
8. Pierce A, Colavizza D, Benaissa M, et al. Molecular cloning and sequence analysis of bovine lactoferrin. Eur J Biochem 1991;196:177-184.
9. Inagaki M, Kikuchi M, Orino K, et al. Purification and quantification of lactoferrin in equine seminal plasma. J Vet Med Sci 2002;64:75-77.
10. Baker EN, Anderson BF, Baker HM, et al. Three-dimensional structure of lactoferrin in various functional states. Adv Exp Med Biol 1994;357:1-12.
11. Brodie AH, Ainscough EW, Baker EN, et al. Synergism and substitution in the lactoferrins. Adv Exp Med Biol 1994;357:33-44.
12. Harrington JP, Stuart J, Jones A. Unfolding of iron and copper complexes of human lactoferrin and transferrin. Int J Biochem 1987;19:1001-1008.
13. Baker EN, Baker HM, Kidd RD. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem Cell Biol 2002;80:27-34.
14. Van der Strate BW, Harmsen MC, The TH, et al. Plasma lactoferrin levels are decreased in end-stage AIDS-patients. Viral Immunol 1999;12:197-203.
15. Britigan BE, Serody JS, Cohen MS. The role of lactoferrin as an anti-inflammatory molecule. Adv Exp Med Biol 1994;357:143-156.
16. Schanbacher FL, Talhouk RS, Murray FA. Biology and origin of bioactive peptides in milk. Livest Prod Sci 1997;50:105-123.
17. Bellamy W, Takase M, Yamauchi K, et al. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992;1121:130-136.
18. Arnold RR, Cole MF, McGhee JR. A bactericidal effect for human lactoferrin. Science 1977;197:263-265.
19. Ellison RT. The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol 1994;357:71-90.
20. Nibbering PH, Ravensbergen E, Welling MM, et al. Human lactoferrin and peptides derived from its N-terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 2001;69:1469-1476.
21. Hoek KS, Milne JM, Grieve PA, et al. Antibacterial activity of bovine lactoferrin-derived peptides. Antimicrob Agents Chemother 1997;41:54-59.
22. Cohen MS, Mao J, Rasmussen GT, et al. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J Infect Dis 1992; 166:1375-1378.
23. Elass-Rochard E, Legrand D, Salmon V, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998;66:486-491.
24. Elass-Rochard E, Roseanu A, Legrand D, et al. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem J 1995;312:839-845.
25. Reiter B. The biological significance of the nonimmunoglobulin protective proteins in milk. In: Fox PF, ed. Developments in dairy chemistry 3. London: Elsevier Applied Science, 1985;281-336.
26. Sanchez L, Calvo M, Brock JH. Biological role of lactoferrin. Arch Dis Child 1992;67:657-661.
27. Matsue M, Tomita S, Nyui S, et al. Suppressive effects of lactoferrin on bleomycin-dependent DNA damage by the iron ion and ascorbate. Biosci Biotechnol Biochem 1994;58:67-71.
28. Matsue M, Matsuyama J, Kiyosawa I. Interaction of lactoferrin with ascorbate and the relationship with bleomycin-dependent DNA damage. Biosci Biotechnol Biochem 1995;59:358-362.
29. Kawakami H, Hiratsuka M, Dosako S. Effects of iron-saturated lactoferrin on iron absorption. Agric Biol Chem 1988;52:903-908.
30. Kawakami H, Dosako S, Nakajima I. Effect of lactoferrin on iron solubility under neutral conditions. Biosci Biotechnol Biochem 1993;57:1376-1377.
31. Mikogami T, Marianne T, Spik G. Effect of intracellular iron depletion by picolinic acid on expression of the lactoferrin receptor in the human colon carcinoma cell subclone HT29-18-C1. Biochem J 1995;308:391-397.
32. Medina I, Tombo I, Satue-Gracia MT, et al. Effects of natural phenolic compounds on the antioxidant activity of lactoferrin in liposomes and oil-in-water emulsions. J Agric Food Chem 2002;50:2392-2399.
33. Mattsby-Baltzer I, Roseanu C, Motas C, et al. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 1996;40:257-262.
34. Damiens E, Mazurier J, el Yazidi I, et al. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim Biophys Acta 1996;1402:277-287.
35. Zimecki M, Mazurier J, Machnicki M, et al. Immunostimulatory activity of lactotransferrin and maturation of CD4-CD8-murine thymocytes. Immunol Lett 1991;30:119-124.
36. Sekine K, Watanabe E, Nakamura J, et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 1997;88:523-526.
37. Yoo YC, Watanabe S, Watanabe R, et al. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 1997;88:184-190.
38. Yi M, Kaneko S, Yu DY, et al. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 1997;71:5997-6002.
39. Sato R, Inanami O, Tanaka Y, et al. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res 1996;57:1443-1446.
40. Hasegawa K, Motsuchi W, Tanaka S, et al. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol 1994;47:73-85.
41. Harmsen MC, Swart PJ, de Bethune M, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995;172:380-388.
42. Superti F, Ammendolia MG, Valenti P et al. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol (Berl) 1997;186:83-91.
43. Esposito JJ, Obljeski JF. Enterovirus type 70 virion and intracellular proteins. J Virol 1976;18:1160-1162.
44. Grover M, Giouzeppos O, Schnagl RD, et al. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acta Paediatr 1997;86:315-316.
45. Britt WJ. Cytomegalovirus. In: Fields BN, Knipe DM, eds. Virology. 2nd ed. New York: Raven Press, 1990;2493-2524.
46. Shimizu K, Matsuzawa H, Okada K, et al. Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell dependent augmentation of natural killer cell activity. Arch Virol 1996;141:1875-1889.
47. Crouch SP, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992;80:235-240.
48. Levy O. Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol 1996;56:263-277.
49. Damiens E, El Yazidi I, Mazurier J. Role of heparan sulphate protenglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur J Cell Biol 1998; 77:344-351.
50. Laquerre S, Argnani R, Anderson DB, et al. Heparan sulfate lactoferrinate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998;72:6119-6130.
51. Sawitzky D. Protein-glycosaminoglycan interactions: infectiological aspects. Med Microbiol Immunol (Berl) 1996;184:155-161.
52. Hu WL, Regoeczi E, Chindemi PA, et al. Lactoferrin interferes with uptake of iron from transferrin and asialotransferrin by the rat liver. Am J Physiol 1993;264:G112-G117.
53. Ji ZS, Mahley RW. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler Thromb 1994;14:2025-2031.
54. Schiff RD, Oliff A. The pathophysiology of murine retrovirus-induced leukemias. Crit Rev Oncol Hematol 1986;5:257-323.
55. Gutteridge JMC. Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J 1991;199:259-261.
56. Kawakami H, Dosako, S, Lönnerdal B. Iron uptake from transferrin and lactoferrin by rat intestinal brush-border membrane vesicles. Am J Physiol 1990;258:G535-G541.
57. Inoue H, Sakai M, Kaida Y, et al. Blood lactoferrin release induced by running exercise in normal volunteers: antibacterial activity. Clin Chim Acta 2004;341:165-172.
58. Akin DT, Lu MQ Lu SJ, et al. Bactericidal activity of different forms of lactoferrin. Adv Exp Med Biol 1994;357:61-70.
59. Brissette CA, Fives-Taylor PM. Actinobacillus actinomycetemcomitans may utilize either actin-dependent or actin-independent mechanisms of invasion. Oral Microbiol Immunol 1999;14:137-142.
60. Mintz KP, Fives-Taylor PM. Binding of the periodontal pathogen Actinobacillus actinomycetemcomitans to extracellular matrix proteins. Oral Microbiol Immunol 1999;14:109-116.
61. Alugupalli KR, Kalfas S, Edwardsson S, et al. Effect of lactoferrin on interaction of Prevotella intermedia with plasma and subepithelial matrix proteins. Oral Microbiol Immunol 1994;9:174-179.
62. Alugupalli KR, Kalfas S, Edwardsson S, et al. Lactoferrin interaction with Actinobacillus actinomycetemcomitans. Oral Microbiol Immunol 1995;10:35-41.
63. Alugupalli KR, Kalfas S. Inhibitory effect of lactoferrin on the adhesion of Actinobacillus actinomycetemcomitans and Prevotella intermedia to fibroblasts and epithelial cells. APMIS 1995;103:154-160.
64. Bellamy W, Wakabayashi H, Takase M, et al. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol (Berl) 1993;182:97-105.
65. Lee WJ, Farmer JL, Hilty M, et al. The protective effects of lactoferrin feeding against endotoxin lethal shock in germ-free piglets. Infect Immun 1999;66:1421-1426.
66. Chierici R, Fanaro S, Saccomandi D, et al. Advances in the modulation of the microbial ecology of the gut in early infancy. Acta Paediatr Suppl 2003;91:56-63.
67. Griffiths EA, Duffy LC, Schanbacher FL, et al. In vitro growth responses of bifidobacteria and enteropathogens to bovine and human lactoferrin. Dig Dis Sci 2003;48:1324-1332.
68. Kruzel ML, Harari Y, Chen CY, et al. The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol 1998;443:167-173.
69. Thomas LL, Wei Xu, Ardon TT. Immobilized lactoferrin is a stimulus for eosinophil activation. J Immunol 2002;169:993-999.